OmniAb, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. Financial results are compared with 2022; that year includes pre-separation carve-out reporting and post-November 1 standalone reporting, so comparability is limited.
Business context
OmniAb licenses antibody-discovery technologies and provides related research services to pharmaceutical and biotechnology partners. Its business model combines technology-access and service fees with development and commercial milestones and potential royalties. At year-end, the company reported 77 active partners, 325 active programs, 28 partner programs in clinical development, one under regulatory review, and three approved partner products. It launched OmniDeep in 2023 and Omni dAb in November 2023.
Key financial metrics
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $34.2 million | $59.1 million | Down 42% |
| License and milestone revenue | $20.7 million | $38.9 million | Down 47% |
| Service revenue | $12.2 million | $18.8 million | Down 35% |
| Royalty revenue | $1.3 million | $1.4 million | Down 6% |
| Research and development expense | $56.5 million | $48.4 million | Up 17% |
| General and administrative expense | $33.3 million | $24.9 million | Up 34% |
| Operating loss | $69.4 million | $26.6 million | Loss widened |
| Net loss | $50.6 million | $22.3 million | Loss widened |
| Net loss per share | $0.51 | $0.26 | Loss per share widened |
| Cash provided by (used in) operating activities | $2.3 million | $(3.6) million | Improved |
Operating and net margins, calculated from reported figures, were approximately negative 203% and negative 148%, respectively, in 2023. The filing does not present a gross margin figure.
At December 31, 2023, cash and cash equivalents were $16.4 million and short-term investments were $70.6 million, totaling approximately $87.0 million. Current assets were $94.9 million and current liabilities $23.1 million. Total liabilities were $60.6 million and stockholders’ equity was $314.6 million. No borrowings are shown as a balance-sheet line item. Operating cash flow was positive despite the net loss, reflecting noncash charges and working-capital movements, including a $26.9 million decrease in accounts receivable. Capital expenditures were $1.6 million; investing cash outflow was $18.4 million, primarily reflecting purchases of short-term investments net of maturities.
Material changes and unusual items
- Revenue fell primarily because 2022 included a $25.0 million milestone for the first U.S. commercial sale of teclistamab. In 2023, OmniAb recognized a $10.0 million milestone for its first EU commercial sale; revenue from other programs also declined.
- R&D and G&A costs increased as the company invested in personnel, facilities, platform development, and public-company operations. Share-based compensation expense rose to $24.8 million from $18.3 million.
- Active partners increased 12% to 77, active programs increased 12% to 325, and active clinical programs plus approved products increased 23% to 32. Approved products remained at three.
- Three partners accounted for 58% of 2023 revenue, compared with 72% in 2022. One partner alone contributed 29% of 2023 revenue.
- Interest income increased to $5.1 million from $0.6 million, largely reflecting interest earned on short-term investments.
Outlook, risks, and contingencies
- Management expects existing cash, cash equivalents, short-term investments, and anticipated operating cash flows to support operations for at least the next 12 months. The company expects continued losses and may need additional capital if cash flows or demand are weaker than anticipated.
- No specific revenue or earnings guidance is provided. Management expects milestones to be an important nearer-term revenue source and royalties to be a potential longer-term source, but their timing and likelihood are uncertain and depend on partners’ development and commercialization decisions.
- Key risks include partner and program concentration; partners’ ability to advance candidates and achieve approvals or sales; revenue volatility; competition and technology adoption; reliance on third-party animal facilities and suppliers; intellectual-property and licensing risks; and the possibility of future financing-related dilution.
- The company entered into a sales agreement allowing up to $100 million of common stock sales through an at-the-market offering; it reported no sales under the agreement in 2023. Warrants with an $11.50 exercise price were out of the money at the filing date.
- Contingent liabilities totaled $4.5 million at year-end, and operating lease liabilities totaled $25.6 million. Management reported no current legal proceedings expected to have a material adverse effect. The filing also describes potential indemnification and tax obligations connected with the separation from Ligand.
- Management concluded disclosure controls and internal control over financial reporting were effective as of year-end. The auditor did not provide an internal-control attestation because of the company’s emerging-growth-company and non-accelerated-filer exemptions.
Important facts for investors to verify
- Whether partner programs continue to progress and whether additional milestones, approvals, or commercial royalties are achieved—and when.
- How revenue and cash receipts evolve given the decline in 2023 revenue and the reliance on a small number of partners.
- Whether operating expenses, cash use, and the stated minimum 12-month liquidity outlook remain consistent with management’s expectations.
- Whether any shares are sold under the $100 million ATM agreement, and the potential dilution from equity awards, warrants, earnout shares, and registered resale shares.
- Whether the 2022-versus-2023 comparison is adjusted for the separation and changes in reporting basis when assessing underlying performance.